Real-world progression-free survival in first-line advanced non-small cell lung cancer treated with immunotherapy-based regimens using a US dataset

Data in Brief

Jenny Lam¹  Yong Yuan²  Lei Yin²  Sophie Gao²  David Stenehjem³  John Hartman³  Solomon Lubinga³  Sumati Rao³  Keith A. Betts³  David Waterhouse⁴ 

[1] Corresponding author.;Analysis Group, Los Angeles, CA, USA;Bristol Myers Squibb, Lawrenceville, NJ, USA;OHC Cincinnati, Cincinnati, OH, USA;

关键词: Non-small cell lung cancer;    Real-world outcomes;    Immunotherapy;    Immune checkpoint inhibitors;   

DOI  :  

来源: DOAJ

【 摘 要 】

While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to specific therapeutic regimens. This supplementary data is supportive to the research article entitled “Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer” [1]. Using electronic health records data from a large demographically and geographically diverse oncology database, we present real-world progression-free survival (rwPFS) outcomes for patients with advanced non-small cell lung cancer in the United States treated with either first-line immunotherapy as monotherapy or single-agent immunotherapy combined with chemotherapy. rwPFS was estimated for patients in each treatment group using Kaplan-Meier methods; analyses were conducted separately for patients with squamous and non-squamous histology and stratified by Eastern Cooperative Oncology Group performance status, tumor programmed death ligand-1 expression, and presence of brain metastases.

【 授权许可】

Unknown